Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)

American Heart Journal

Volumn 169, Issue 4, 2015, Pages 464-471.e2

  Lip, Gregory Y H ^a   Hammerstingl, Christoph ^b   Marin, Francisco ^c   Cappato, Riccardo ^d   Meng, Isabelle Ling ^e   Kirsch, Bodo ^e   Morandi, Eolo ^f   Van Eickels, Martin ^e   Cohen, Ariel ^g  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e BAYER PHARMA AG   (Germany)

^f As criaturas de Prometeu   (Brazil)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; DRUG DOSE REDUCTION; DRUG EFFICACY; FOLLOW UP; HEALTH CARE QUALITY; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM THROMBOSIS; HUMAN; INCIDENCE; INTERVENTION STUDY; LEFT ATRIAL APPENDAGE THROMBUS; NONVALVULAR ATRIAL FIBRILLATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; ECHOGRAPHY; FEMALE; HEART DISEASES; MALE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CATHETER ABLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; FACTOR XA INHIBITORS; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; RETROSPECTIVE STUDIES; THIOPHENES; THROMBOSIS; TREATMENT OUTCOME;

EID: 84927570044     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.12.020     Document Type: Article

References (56)

1. N.M. Al Saady, O.A. Obel, and A.J. Camm Left atrial appendage: structure, function, and role in thromboembolism Heart 82 1999 547 554
2. L. Azoulay, S. Dell'aniello, and T.A. Simon Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes Eur Heart J 35 2014 1881 1887
3. P. Gallego, V. Roldan, and F. Marin Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 2013 1189 1198
4. G. Corrado, G. Tadeo, and S. Beretta Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation Chest 115 1999 140 143
5. R. Nagarakanti, M.D. Ezekowitz, and J. Oldgren Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
6. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography Ann Intern Med 128 1998 639 647
7. K. Seidl, M. Rameken, and A. Drogemuller Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study J Am Coll Cardiol 39 2002 1436 1442
8. I.W. Black, D. Fatkin, and K.B. Sagar Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study Circulation 89 1994 2509 2513
9. M. Saeed, A. Rahman, and A. Afzal Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation Int J Cardiol 113 2006 401 405
10. A.L. Klein, R.D. Murray, and R.A. Grimm Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation J Am Coll Cardiol 37 2001 691 704
11. W.J. Manning, R.M. Weintraub, and C.A. Waksmonski Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study Ann Intern Med 123 1995 817 822
12. A.J. Camm, P. Kirchhof, and G.Y.H. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
13. A.L. Klein, R.A. Grimm, and R.D. Murray Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 2001 1411 1420
14. B. Akdeniz, S. Türker, and V. Öztürk Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin Int J Cardiol 98 2005 49 55
15. L.J. Collins, D.I. Silverman, and P.S. Douglas Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution Circulation 92 1995 160 163
16. W.A. Jaber, D.L. Prior, and M. Thamilarasan Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study Am Heart J 140 2000 150 156
17. J.P. Piccini, S.R. Stevens, and Y. Lokhnygina Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
18. G. Flaker, R.D. Lopes, and S.M. Al Khatib Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) J Am Coll Cardiol 63 2014 1082 1087
19. S. Husted, R. De Caterina, and F. Andreotti Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel Thromb Haemost 111 2014 781 782
20. R. De Caterina, S. Husted, and L. Wallentin General mechanisms of coagulation and targets of anticoagulants (section I). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Thromb Haemost 109 2013 569 579
21. A.J. Camm, G.Y.H. Lip, and R. De Caterina 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
22. A. Vidal, and G. Vanerio Dabigatran and left atrial appendage thrombus J Thromb Thrombolysis 34 2012 545 547
23. L. Di Biase, J.D. Burkhardt, and G. Gilbert Dabigratan has a higher risk of left atrial appendage thrombus formation in patients with AF when compared to warfarin and rivaroxaban Circulation 2013 [Dallas, USA, Abstract 14308]
24. C. Hammerstingl, B. Pötzsch, and G. Nickenig Resolution of giant left atrial appendage thrombus with rivaroxaban Thromb Haemost 109 2013 583 584
25. J. Takasugi, H. Yamagami, and T. Okata Dissolution of the left atrial appendage thrombus with rivaroxaban therapy Cerebrovasc Dis 36 2013 322 323
26. T. Kawakami, H. Kobayakawa, and H. Ohno Resolution of left atrial appendage thrombus with apixaban Thromb J 11 2013 26
27. S. Dobashi, T. Fujino, and T. Ikeda Use of apixaban for an elderly patient with left atrial thrombus BMJ Case Rep 2014 2014
28. M. Lambers, G. Nickenig, and H.J. Hertfelder Direct acting oral anticoagulants are more effective than vitamin-K-antagonists for the resolution of established left atrial thrombi in patients with atrial fibrillation Clin Res Cardiol 2014 [Abstract v1324]
29. E. Perzborn, S. Roehrig, and A. Straub Rivaroxaban: a new oral factor Xa inhibitor Arterioscler Thromb Vasc Biol 30 2010 376 381
30. D.S. Conway, P. Buggins, and E. Hughes Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation J Am Coll Cardiol 43 2004 2075 2082
31. H.S. Lim, S.R. Willoughby, and C. Schultz Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm J Am Coll Cardiol 61 2013 852 860
32. K. Kumagai, M. Fukunami, and M. Ohmori Increased intracardiovascular clotting in patients with chronic atrial fibrillation J Am Coll Cardiol 16 1990 377 380
33. V. Roldan, F. Marin, and A.D. Blann Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation Eur Heart J 24 2003 1373 1380
34. G.Y. Lip, R.D. Watson, and S.P. Singh ABC of atrial fibrillation. Drugs for atrial fibrillation BMJ 311 1995 1631 1634
35. N. Vene, A. Mavri, and K. Kosmelj High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy Thromb Haemost 90 2003 1163 1172
36. T. Maehama, H. Okura, and K. Imai Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation J Cardiol 56 2010 118 124
37. P.M. Ridker, N. Rifai, and M.J. Stampfer Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101 2000 1767 1772
38. P.M. Ridker Role of inflammatory biomarkers in prediction of coronary heart disease Lancet 358 2001 946 948
39. V. Roldan, F. Marin, and P. Marco Hypofibrinolysis in atrial fibrillation Am Heart J 136 1998 956 960
40. H. Cai, Z. Li, and A. Goette Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke Circulation 106 2002 2854 2858
41. V. Roldan, F. Marin, and P. Marco Anticoagulant therapy modifies fibrinolytic dysfunction in chronic atrial fibrillation Haemostasis 30 2000 219 224
42. G.P. Luo, B. Ni, and X. Yang von Willebrand factor: more than a regulator of hemostasis and thrombosis Acta Haematol 128 2012 158 169
43. V. Roldan, F. Marin, and B. Muina Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients J Am Coll Cardiol 57 2011 2496 2504
44. N. Ammash, E.A. Konik, and R.D. McBane Left atrial blood stasis and von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation Arterioscler Thromb Vasc Biol 31 2011 2760 2766
45. G.Y.H. Lip, D. Lane, and C. van Walraven Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation Stroke 37 2006 2294 2300
46. D.S. Conway, L.A. Pearce, and B.S. Chin Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation Circulation 107 2003 3141 3145
47. P. Gallego, V. Roldan, and G.Y. Lip Novel oral anticoagulants in cardiovascular disease J Cardiovasc Pharmacol Ther 19 2014 34 44
48. M. Kuruvilla, and C. Gurk-Turner A review of warfarin dosing and monitoring Proc (Bayl Univ Med Cent) 14 2001 305 306
49. S. Ogawa, Y. Koretsune, and M. Yasaka Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents Circ J 75 2011 1539 1547
50. J. Ansell Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 5 2007 60 64
51. J. Fareed, D. Hoppensteadt, and J. Cunanan Effect of dabigatran and rivaroxaban on thrombomodulin mediated activation of protein C and thrombin activated fibrinolysis inhibitor (TAFI) FASEB J 2012 [Abstract 832.7]
52. D.M. Monroe, and M. Hoffman What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26 2006 41 48
53. B. Akdeniz, S. Türker, and V. Öztürk Cardioversion under the guidance of transesophageal echochardiography in persistent atrial fibrillation: results with low molecular weight heparin Int J Cardiol 98 2005 49 55
54. S. Fukuda, H. Watanabe, and K. Shimada Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation J Cardiol 58 2011 266 277
55. D. Wrisley, A. Giambartolomei, and I. Lee Left atrial ball thrombus: review of clinical and echocardiographic manifestations with suggestions for management Am Heart J 121 1991 1784 1790
56. A.G. Fraser, G.D. Angelini, and S. Ikram Left atrial ball thrombus: echocardiographic features and clinical implications Eur Heart J 9 1988 672 677